Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spark Therapeutics Now Targets 2017 For US Approval Of First Retinal Gene Therapy

Executive Summary

Two manufacturing control assays have taken longer to develop than previously thought, putting back completion of a BLA submission to early 2017 for US company Spark Therapeutics, while further progress has been made in the company’s early-stage hemophilia gene therapy program.

Advertisement

Related Content

Keeping Track Of New Drugs: US FDA Review Queue Adds Spark Gene Therapy, Amgen Migraine Antibody, Bayer Oncologic
Allergan’s RetroSense Buy Marks Move Into Gene Therapy
Biopharma Quarterly Dealmaking Statistics, Q2 2016
Can FDA's Breakthrough Program Finally Midwife Gene Therapy?
Spark Restores Vision In Phase III; CEO Hopes To Lead Gene Therapy Field
EU's CHMP Clears Europe's First Gene Therapy, UniQure's Glybera

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel